Sociodemographic and Illness-Related Indicators to Predict the Status of Neuromyelitis Optica Spectrum Disorder (NMOSD) Five Years after Disease Onset.
EDSS
long-term course
neuromyelitis optica spectrum disorder
predictors
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
29 Jan 2022
29 Jan 2022
Historique:
received:
20
12
2021
revised:
29
12
2021
accepted:
25
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
16
2
2022
Statut:
epublish
Résumé
Neuromyelitis Optica Spectrum Disorder (NMOSD) is an autoimmune demyelinating disease of the central nervous system. Currently, no factors have been identified to predict the long-term course of NMOSD. To counter this, we analyzed data of 58 individuals with NMOSD at disease onset and about five years later. Medical records of 58 individuals with NMOSD (mean age: 31.13 years at disease onset; 86.2% female) were retrospectively analyzed. At baseline, a thorough medical and disease-related examination was performed; the same examination was repeated about five years later at follow-up, including treatment-related information. Mean outcome measure was the difference in EDSS (Expanded Disease Severity Scale) scores between baseline and follow-up. Mean disease duration was 4.67 years. Based on the differences of the EDSS scores between baseline and follow-up, participants were categorized as improving ( Among a smaller sample of individuals with NMOSD followed-up about five years later, individuals deteriorating over time reported a higher progression index, while the annualized relapse rate was unrelated to the progress of disease. Overall, it appears that the course of NMOSD over a time lapse of about five years after disease onset is highly individualized. Accordingly, treatment regimen demands a highly individually tailored approach.
Sections du résumé
BACKGROUND
BACKGROUND
Neuromyelitis Optica Spectrum Disorder (NMOSD) is an autoimmune demyelinating disease of the central nervous system. Currently, no factors have been identified to predict the long-term course of NMOSD. To counter this, we analyzed data of 58 individuals with NMOSD at disease onset and about five years later.
METHODS
METHODS
Medical records of 58 individuals with NMOSD (mean age: 31.13 years at disease onset; 86.2% female) were retrospectively analyzed. At baseline, a thorough medical and disease-related examination was performed; the same examination was repeated about five years later at follow-up, including treatment-related information. Mean outcome measure was the difference in EDSS (Expanded Disease Severity Scale) scores between baseline and follow-up.
RESULTS
RESULTS
Mean disease duration was 4.67 years. Based on the differences of the EDSS scores between baseline and follow-up, participants were categorized as improving (
CONCLUSIONS
CONCLUSIONS
Among a smaller sample of individuals with NMOSD followed-up about five years later, individuals deteriorating over time reported a higher progression index, while the annualized relapse rate was unrelated to the progress of disease. Overall, it appears that the course of NMOSD over a time lapse of about five years after disease onset is highly individualized. Accordingly, treatment regimen demands a highly individually tailored approach.
Identifiants
pubmed: 35160189
pii: jcm11030734
doi: 10.3390/jcm11030734
pmc: PMC8836947
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
N Engl J Med. 2019 Aug 15;381(7):614-625
pubmed: 31050279
Int J Mol Sci. 2021 Aug 11;22(16):
pubmed: 34445343
Neuropathol Appl Neurobiol. 2020 Apr;46(3):199-218
pubmed: 31353503
Handb Clin Neurol. 2014;122:581-99
pubmed: 24507536
BMC Neurol. 2014 Mar 25;14:58
pubmed: 24666846
Ann Neurol. 2016 Feb;79(2):206-16
pubmed: 26537743
Eur J Neurol. 2011 Jun;18(6):836-41
pubmed: 21087360
J Clin Med. 2020 May 02;9(5):
pubmed: 32370288
Neurology. 2007 Dec 11;69(24):2221-31
pubmed: 17928579
Mult Scler Relat Disord. 2015 Mar;4(2):95-103
pubmed: 25787185
Neurology. 1999 Sep 22;53(5):1107-14
pubmed: 10496275
Brain Pathol. 2013 Nov;23(6):647-60
pubmed: 24118482
Mult Scler Relat Disord. 2018 May;22:161-165
pubmed: 29775851
Eur Radiol. 2020 Sep;30(9):5048-5058
pubmed: 32335748
Nat Rev Dis Primers. 2020 Oct 22;6(1):85
pubmed: 33093467
Mult Scler Relat Disord. 2019 Jul;32:81-87
pubmed: 31063950
J Neurol Sci. 2017 Feb 15;373:134-137
pubmed: 28131170
Neurology. 2015 Jul 14;85(2):177-89
pubmed: 26092914
Mult Scler. 2017 Mar;23(3):360-361
pubmed: 28260418
Acta Neurol Belg. 2015 Dec;115(4):635-42
pubmed: 25944511
Brain. 2007 May;130(Pt 5):1194-205
pubmed: 17282996
Continuum (Minneap Minn). 2010 Oct;16(5 Multiple Sclerosis):105-21
pubmed: 22810601
Neurol Ther. 2021 Dec;10(2):767-783
pubmed: 34046846
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Continuum (Minneap Minn). 2016 Aug;22(3):864-96
pubmed: 27261687
J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):639-647
pubmed: 28572277
Lancet Neurol. 2007 Sep;6(9):805-15
pubmed: 17706564
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Mult Scler Relat Disord. 2017 Apr;13:93-97
pubmed: 28427710
Neurology. 2006 May 23;66(10):1485-9
pubmed: 16717206
Mult Scler Relat Disord. 2021 Feb;48:102685
pubmed: 33321342
J Neurol Neurosurg Psychiatry. 2018 Apr;89(4):346-351
pubmed: 29030418
Neurology. 2015 Mar 17;84(11):1165-73
pubmed: 25695963
Mayo Clin Proc. 2017 Apr;92(4):663-679
pubmed: 28385199